CHARLES SCHWAB INVESTMENT MANAGEMENT INC
Position in BCAX — Bicara Therapeutics Inc.
CIK 884546
SAN FRANCISCO, CA
Position in BCAX
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$10,851,130
+$5,600,469 QoQ
Shares Held
365,481
+38.4% QoQ
Ownership
0.552%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#30
of 171 holders
Holding Since
Dec 2024
7 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in BCAX Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026CHARLES SCHWAB INVESTMENT MANAGEMENT INC holds $7,346,663,053 across 299 Biotechnology names. BCAX ranks #103 (0.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
2,041,282 | $1,013,966,007 | |
| 2 | REGN |
Regeneron Pharmaceuticals, Inc.
|
846,306 | $527,705,642 | |
| 3 | RVMD |
Revolution Medicines, Inc.
|
1,917,025 | $359,020,441 | |
| 4 | MRNA |
Moderna, Inc.
|
4,838,884 | $338,867,045 | |
| 5 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
755,377 | $227,391,137 | |
| 6 | INCY |
Incyte Corp
|
1,692,439 | $191,854,884 | |
| 7 | RPRX |
Royalty Pharma plc
|
3,083,528 | $172,893,414 | |
| 8 | CYTK |
Cytokinetics Inc
|
1,565,781 | $133,388,883 |
All Filings in BCAX
Export CSV
7 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $10,851,130 | 365,481 | Shares | Sole | 2026-08-14 | |
| 2026-03-31 | $5,250,661 | 263,985 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $4,580,200 | 272,145 | Shares | Sole | 2026-02-13 | |
| 2025-09-30 | $4,435,032 | 280,876 | Shares | Sole | 2025-11-10 | |
| 2025-06-30 | $1,793,462 | 193,053 | Shares | Sole | 2025-08-12 | |
| 2025-03-31 | $1,993,642 | 153,004 | Shares | Sole | 2025-09-15 | |
| 2024-12-31 | $2,731,177 | 156,784 | Shares | Sole | 2025-02-06 | |
| No filing history on record for this holder in this stock. | ||||||